Novo Nordisk Reduces Out-of-Pocket Costs for Popular GLP-1 Drugs Amidst Demand and Trump Administration Pressure
Novo Nordisk cuts Wegovy and Ozempic costs, offering discounts from $199 monthly for self-pay and new patients, driven by competition and Trump administration.
NBC NewsNovo Nordisk to offer select doses of Ozempic, Wegovy at a steep discount
New York SunMaker of Wegovy and Ozempic Slashes Prices as Competition Among Popular Weight-Loss Drugs Ramps Up
CBS NewsNovo Nordisk slashes out-of-pocket prices for Wegovy and Ozempic for some customers
ABC NewsNovo chops Wegovy prices, but doctors still see affordability challenges for patients
Overview
Novo Nordisk is implementing significant price reductions for its popular GLP-1 drugs, Wegovy and Ozempic, making them more accessible to self-pay and new patients.
Starter doses of these medications are now available for $199 per month, with higher doses priced at $349, effective until the end of March for temporary deals.
This move comes amidst increasing competition in the GLP-1 market and pressure from the Trump administration to lower drug costs for Medicare, Medicaid, and cash-paying consumers.
Approximately one in eight U.S. adults use GLP-1 drugs, but many, including about half of current users, find the treatments difficult to afford due to high costs.
Consumers can access these new prices nationwide through various channels, while Eli Lilly also plans similar price breaks for its competing weight-loss drug, Zepbound.
Analysis
Center-leaning sources cover this story neutrally by presenting both the drugmaker's price reductions and the ongoing affordability challenges for patients. They balance corporate announcements with expert analysis and patient impact, avoiding loaded language. The reporting provides factual details on the price changes while immediately contextualizing their real-world effect on access.